Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

The first launch is a down payment: this earnings season rewards the label that funds the next one

Kura, Autolus, ADC Therapeutics and others are using first-product revenue to underwrite a second act. The risk is trying to do both at once.

18 Nov 2026 · CompePharma editorial

The pattern behind the quarter

Read the third-quarter reports side by side and the headline numbers matter less than what sits next to them. Kura Oncology reported KOMZIFTI net product revenue of $13.9 million, up 53% sequentially, with total prescriptions up 65%. In the same release it announced eight ASH abstracts, FDA alignment on a roughly 40-patient registrational study for darlifarnib, and combination studies slated for 2027. Autolus posted AUCATZYL revenue of $41.2 million, up 95% year over year, and has trials enrolling in lupus nephritis, pediatric ALL and progressive multiple sclerosis. ADC Therapeutics reported $21 million of net product revenue and pointed to ASH abstracts across multiple B-cell malignancies for ZYNLONTA.

This is not coincidence. The first approved indication is no longer the destination. It is the platform, and the companies doing best this season are treating it that way.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →
Opinion · CompePharma View

Gross margin is the number that turns a launch into a business

Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.

18 Nov 2026 · CompePharma editorial